The response rate in Japanese patients with MET exon 14 skipping highlights the importance of molecular testing at initial diagnosis of advanced NSCLC, and is particularly relevant following the approval in Japan of a companion diagnostic using liquid or tissue biopsy samples for MET exon 14 skipping alterations. The gene discussed is MET; the disease is non-small cell lung carcinoma.